(CAR).CD19-CD28-zeta-2A-iCasp9-IL15-transduced cord blood natural killer cells
Showing 1 - 25 of >10,000
CNS Lymphoma Trial in Duarte (procedure, biological, drug)
Recruiting
- Central Nervous System Lymphoma
- Aspiration
- +10 more
-
Duarte, CaliforniaCity of Hope Medical Center
Dec 8, 2022
B-Lymphoid Malignancies, Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia Trial in Houston (Fludarabine,
Active, not recruiting
- B-Lymphoid Malignancies
- +3 more
- Fludarabine
- +4 more
-
Houston, TexasUniversity of Texas MD Anderson Cancer Center
Aug 1, 2022
Recurrent DLBCL, Recurrent Mantle Cell Lymphoma, Refractory DLBCL Trial in Duarte (Autologous
Active, not recruiting
- Recurrent Diffuse Large B-Cell Lymphoma
- +4 more
- Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells
- +2 more
-
Duarte, CaliforniaCity of Hope Medical Center
Mar 28, 2022
Adult Grade III Lymphomatoid Granulomatosis, Cutaneous B-cell Non-Hodgkin Lymphoma, MALT Trial in Duarte (biological, procedure,
Active, not recruiting
- Adult Grade III Lymphomatoid Granulomatosis
- +23 more
- autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells
- +2 more
-
Duarte, CaliforniaCity of Hope Medical Center
Jan 4, 2023
Adult Acute Myeloid Leukemia in Remission, Acute Biphenotypic Leukemia, Early Relapse of Acute Myeloid Leukemia Trial in Duarte
Active, not recruiting
- Adult Acute Myeloid Leukemia in Remission
- +12 more
- cyclophosphamide
- +4 more
-
Duarte, CaliforniaCity of Hope Medical Center
Feb 17, 2022
CD19 Positive, Mantle Cell Lymphoma, Recurrent DLBCL Trial in Houston (procedure, drug, biological)
Withdrawn
- CD19 Positive
- +6 more
- Autologous Hematopoietic Stem Cell Transplantation
- +7 more
-
Houston, TexasM D Anderson Cancer Center
Jan 27, 2020
B Acute Lymphoblastic Leukemia With t(v;11q23.3); KMT2A Rearranged, Recurrent B Acute Lymphoblastic Leukemia, Recurrent Chronic
Terminated
- B Acute Lymphoblastic Leukemia With t(v;11q23.3); KMT2A Rearranged
- +16 more
- Autologous CD19-CD8-CD28-CD3zeta-CAR-mbIL15-HER1t T Cells
- +2 more
-
Houston, TexasM D Anderson Cancer Center
May 28, 2021
Hematological Malignancy Trial in Houston (Fludarabine Phosphate, Cyclophosphamide, CAR.5/IL15-transduced CB-NK cells)
Not yet recruiting
- Hematological Malignancy
- Fludarabine Phosphate
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Dec 5, 2022
Non Hodgkin's Lymphoma Trial in Beijing (TRAC and Power3 Genes Knock-out Allogeneic CD19-targeting CAR-T cell (ATHENA CAR-T),
Not yet recruiting
- Non Hodgkin's Lymphoma
- TRAC and Power3 Genes Knock-out Allogeneic CD19-targeting CAR-T cell (ATHENA CAR-T)
- +2 more
-
Beijing, China
- +2 more
Aug 23, 2023
B-cell Non Hodgkin Lymphoma Trial in Hanzhou (CB dualCAR-NK19/70)
Not yet recruiting
- B-cell Non Hodgkin Lymphoma
- CB dualCAR-NK19/70
-
Hanzhou, Zhejiang, China2nd Affiliated Hospital, School of Medicine, Zhejiang University
Dec 25, 2022
Advanced Renal Cell Carcinoma, Advanced Mesothelioma, Advanced Osteosarcoma Trial in Houston (CAR.70/IL15-transduced CB-derived
Not yet recruiting
- Advanced Renal Cell Carcinoma
- +2 more
- CAR.70/IL15-transduced CB-derived NK cells
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Jan 27, 2023
Pancreatic Cancer, Ovarian Cancer, Adenocarcinoma Trial in Houston (TROP2-CAR-NK, Cyclophosphamide, Fludarabine)
Not yet recruiting
- Pancreatic Cancer
- +2 more
- TROP2-CAR-NK
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Jun 27, 2023
Refractory B-Cell Non-Hodgkin Lymphoma, Refractory B-Cell Small Lymphocytic Lymphoma, Relapsed Adult ALL Trial in Houston
Recruiting
- Refractory B-Cell Non-Hodgkin Lymphoma
- +4 more
- CD19.CAR-aNKT cells
- +2 more
-
Houston, Texas
- +1 more
Aug 19, 2022
B-cell Non Hodgkin Lymphoma Trial in Hanzhou (anti-CD19 CAR-NK)
Not yet recruiting
- B-cell Non Hodgkin Lymphoma
- anti-CD19 CAR-NK
-
Hanzhou, Zhejiang, China2nd Affiliated Hospital, School of Medicine, Zhejiang University
Jul 21, 2022
Relapsed or Refractory CD19+ B-cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small
Recruiting
- Relapsed or Refractory CD19+ B-cell Lymphoma
- +2 more
- TBI-2001
- +2 more
-
Toronto, Ontario, CanadaPrincess Margaret Cancer Centre
Jul 26, 2023
B-Cell Non Hodgkin Lymphoma, B-Cell Acute Lymphoblastic Leukemia Trial in Hanoi (anti-CD19 CAR T-cells)
Recruiting
- B-Cell Non Hodgkin Lymphoma
- B-Cell Acute Lymphoblastic Leukemia
- anti-CD19 CAR T-cells
-
Hanoi, VietnamVinmec Research Institute of Stem Cell and Gene Technology
Sep 5, 2023
CD19-positive Relapsed or Refractory B-cell Malignancies Trial in Hefei (UTAA09 cells for infusion, Fludarabine,
Not yet recruiting
- CD19-positive Relapsed or Refractory B-cell Malignancies
- UTAA09 cells for infusion
- +2 more
-
Hefei, Anhui, ChinaThe First Affiliated Hospital of USTC (AnHui Provincial Hospital
Oct 13, 2023
Systemic Lupus Erythematosus Trial (CD19 Universal CAR-?d T Cells)
Not yet recruiting
- Systemic Lupus Erythematosus
- CD19 Universal CAR-γδ T Cells
- (no location specified)
Oct 24, 2023
Recurrent DLBCL, Recurrent DLBCL, Not Otherwise Specified, Recurrent Grade 3b Follicular Lymphoma Trial in Seattle
Recruiting
- Recurrent Diffuse Large B-Cell Lymphoma
- +8 more
- Cyclophosphamide
- +3 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Dec 30, 2022
Non Hodgkin's Lymphoma Trial in Beijing (Allogenic CD19-CAR-?dT cell, Fludarabine, Cyclophosphamide)
Recruiting
- Non Hodgkin's Lymphoma
- Allogenic CD19-CAR-γδT cell
- +2 more
-
Beijing, Beijing, China
- +1 more
Jan 31, 2023
Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia Trial in Houston (autologous or syngeneic PBTLs and EBV-CTLs)
Active, not recruiting
- Non-Hodgkin Lymphoma
- Chronic Lymphocytic Leukemia
- autologous or syngeneic PBTLs and EBV-CTLs
-
Houston, Texas
- +1 more
Feb 6, 2022
Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma Trial in Duarte (Acalabrutinib,
Recruiting
- Recurrent Mantle Cell Lymphoma
- Refractory Mantle Cell Lymphoma
- Acalabrutinib
- CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes
-
Duarte, CaliforniaCity of Hope Comprehensive Cancer Center
Jun 16, 2022
B-cell NHL, CLL Trial (CARCIK-CD19)
Not yet recruiting
- B-cell NHL
- CLL
- CARCIK-CD19
- (no location specified)
May 19, 2023
B-cell Acute Lymphoblastic Leukemia Trial in Nanchang (Human CD19 Targeted DASH CAR-T Cells Injection)
Recruiting
- B-cell Acute Lymphoblastic Leukemia
- Human CD19 Targeted DASH CAR-T Cells Injection
-
Nanchang, Jiangxi, ChinaThe Second Affiliated Hospital of Nanchang University
Dec 13, 2022
Neuroblastoma Trial in Houston (GINAKIT Cells, Cyclophosphamide, Fludarabine)
Active, not recruiting
- Neuroblastoma
- GINAKIT Cells
- +2 more
-
Houston, TexasTexas Children's Hospital
Jan 18, 2023